The Relationship of Conduction Disorder and Prognosis in Patients with Acute Coronary Syndrome
Table 2
Baseline characteristics and clinical outcomes in the patients with LBBB or RBBB or NICD.
Before propensity score matching
After propensity score matching
LBBB
RBBB
NICD
value
LBBB
RBBB
NICD
-Value
Number general demographics
1118
2042
232
125
125
125
Age (years)
70 (13.1)a
69 (13.9)b
66 (13.6)c
<0.001
66 (14.1)
66 (14.4)
66 (14.1)
0.975
Male sex (%)
364 (32.56)a
570 (27.91)b
46 (19.83)c
<0.001
104 (83.20)
102 (81.6)
102 (81.6)
0.930
BMI (kg/m2)
24.46 (4.34)a
24.95 (4.40)b
25.74 (4.25)c
<0.001
25.81 (4.91)
25.90 (4.24)
25.70 (4.34)
0.687
Comorbidities
Diabetes mellitus (%)
434 (38.82)a
733 (35.90)a
112 (48.28)b
<0.001
63 (50.40)
64 (51.20)
66 (52.80)
0.928
Hypertension (%)
629 (56.26)a
1156 (56.61)a
154 (66.38)b
0.013
83 (66.40)
86 (68.80)
87 (69.60)
0.852
COPD (%)
61 (5.46)
214 (6.31)
13 (5.60)
0.272
5 (4.00)
5 (4.00)
6 (4.80)
0.937
ESRD (%)
184 (16.46)a
246 (12.05)b
50 (21.55)a
<0.001
32 (25.60)
27 (21.60)
29 (23.20)
0.754
Smoking (%)
118 (10.55)
236 (11.56)
33 (14.22)
0.263
13 (10.40)
12 (9.60)
15 (12.00)
0.822
Prior GI bleeding (%)
148 (13.24)
228 (11.17)
31 (13.36)
0.185
16 (12.80)
9 (7.20)
15 (12.00)
0.300
Prior stroke (%)
89 (7.96)
122 (5.97)
16 (6.90)
0.101
7 (5.60)
7 (5.60)
5 (4.00)
0.801
HF (%)
483 (43.20)a
533 (26.10)b
102 (43.97)a
<0.001
55 (44.00)
65 (52.00)
58 (46.40)
0.430
Valvular heart disease (%)
64 (6.96)
84 (5.43)
11 (5.95)
0.209
—
—
—
—
Medication
Antiplatelet agent
Aspirin (%)
689 (61.63)
1200 (58.77)
143 (61.64)
0.250
82 (65.60)
91 (72.80)
82 (65.60)
0.371
Clopidogrel (%)
547 (48.93)
937 (45.89)
112 (48.28)
0.243
64 (51.20)
72 (57.60)
66 (52.80)
0.572
Ticagrelor (%)
190 (16.99)
336 (16.45)
30 (12.93)
0.312
21 (16.80)
20 (16.00)
15 (12.00)
0.522
ACEI/ARB/Entresto (%)
600 (53.67)
1009 (49.41)
118 (50.86)
0.073
67 (53.60)
72 (57.60)
67 (53.60)
0.764
β-blocker (%)
662 (59.21)a
1096 (53.67)b
132 (56.90)a,b
0.010
81 (64.80)
84 (67.20)
81 (64.80)
0.899
MRA or diuretic (%)
358 (32.02)a
433 (21.20)b
73 (31.47)a
<0.001
44 (35.20)
46 (36.80)
46 (36.80)
0.955
Lipid-lowering agents (%)
594 (53.13)
1058 (51.81)
132 (56.90)
0.308
74 (59.20)
70 (56.00)
80 (64.00)
0.431
Left ventricular performance
Mean LVEF (%)
41.00 (19.47)a
47.73 (20.82)b
34.57 (20.02)c
<0.001
35.39 (16.06)
35.59 (18.11)
35.05 (19.99)
0.549
F/U period (years)
1.4 (1.1)a
2.0 (1.7)b
1.6 (1.4)c
<0.001
—
—
—
—
Data are expressed as mean (standard deviation) or as number (percentage). Different letters (a, b) associated with different groups indicate significant difference (at 0.05 level) by Bonferroni multiple comparison procedure. Abbreviation: LBBB: left bundle branch block; RBBB: right bundle branch block; NICD: nonspecific intraventricular conduction delay; BMI: body mass index; PAOD: peripheral arterial occlusive disease; COPD: chronic obstructive pulmonary disease; ESRD: end-stage renal disease; GI: gastrointestinal; HF: heart failure; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; MRA: mineralocorticoid receptor antagonist; LVEF: left ventricular ejection fraction; F/U: follow-up.
